ChemoCentryx, Inc.
(NASDAQ : CCXI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.38%430.140.0%$5769.95m
BNTXBioNTech SE -5.53%333.480.0%$994.80m
NVAXNovavax, Inc. -3.55%248.1679.4%$950.95m
SNSSSunesis Pharmaceuticals, Inc. -0.46%8.650.7%$604.67m
AMGNAmgen, Inc. -0.67%213.611.4%$550.92m
GILDGilead Sciences, Inc. -0.70%71.191.0%$455.28m
REGNRegeneron Pharmaceuticals, Inc. -1.18%638.902.7%$418.56m
TECHBio-Techne Corp. 0.37%538.884.5%$356.85m
ILMNIllumina, Inc. -0.09%432.823.5%$356.73m
BIIBBiogen, Inc. -0.51%291.711.7%$309.48m
VRTXVertex Pharmaceuticals, Inc. -0.80%183.611.9%$245.25m
ISEEIVERIC bio, Inc. 0.86%16.370.0%$193.25m
DVAXDynavax Technologies Corp. 1.17%19.835.7%$156.65m
LIFEaTyr Pharma, Inc. -17.87%10.252.1%$156.36m
BGNEBeiGene Ltd. -1.53%379.521.3%$144.32m

Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.